This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Kala Pharmaceuticals (KALA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Kala Pharma (KALA) delivered earnings and revenue surprises of 4.44% and -40.77%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Kala Pharmaceuticals (KALA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Kala Pharma (KALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Kala Pharmaceuticals (KALA) Q2 Earnings Expected to Decline
by Zacks Equity Research
Kala Pharma (KALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kala Pharmaceuticals (KALA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Kala Pharma (KALA) delivered earnings and revenue surprises of 3.92% and -10.28%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will look forward to regular top and bottom-line numbers and updates on the merger synergies when Viatris (VTRS) reports Q1 results.
Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports first-quarter 2021 results.
Is a Beat in the Cards for Twist (TWS) This Earnings Season?
by Zacks Equity Research
Investors will focus on the top-line and bottom-line numbers when Twist (TWST) reports fiscal second-quarter 2021 results.
Kala Pharmaceuticals (KALA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Kala Pharma (KALA) delivered earnings and revenue surprises of -19.57% and -6.44%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Kala Pharmaceuticals (KALA) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Kala Pharma (KALA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kala Pharmaceuticals (KALA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kala Pharma (KALA) delivered earnings and revenue surprises of -13.64% and 9.74%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Kala Pharmaceuticals (KALA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Kala Pharma (KALA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: GILD's Veklury Approved, NVAX Provides Vaccine Update & More
by Zacks Equity Research
Gilead (GILD) and Novavax (NVAX) continue to be in the spotlight on coronavirus-related updates.
Is the Options Market Predicting a Spike in Kala Pharmaceuticals (KALA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Kala Pharmaceuticals (KALA) stock based on the movements in the options market lately.
Kala Pharmaceuticals (KALA) Looks Good: Stock Adds 6% in Session
by Zacks Equity Research
Kala Pharmaceuticals (KALA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Kala Pharmaceuticals (KALA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kala Pharma (KALA) delivered earnings and revenue surprises of 0.00% and 9.89%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Kala Pharmaceuticals (KALA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Kala Pharma (KALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Kala Pharmaceuticals (KALA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (KALA) Outperforming Other Medical Stocks This Year?
Top Ranked Momentum Stocks to Buy for May 26th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 26th
Has Kala Pharmaceuticals (KALA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (KALA) Outperforming Other Medical Stocks This Year?
Kala Pharmaceuticals (KALA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Kala Pharma (KALA) delivered earnings and revenue surprises of -5.88% and -57.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Lineage Cell (LCTX) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Lineage Cell's (LCTX) Q1 earnings call, investor focus will be on its progress with the pipeline candidate OpRegen, currently being developed for treating dry AMD, as well as other pipeline updates.
Kala Pharmaceuticals (KALA) Is Up 2.56% in One Week: What You Should Know
by Zacks Equity Research
Does Kala Pharmaceuticals (KALA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Kala Pharmaceuticals' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Kala Pharmaceuticals.
Is Kala Pharmaceuticals (KALA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (KALA) Outperforming Other Medical Stocks This Year?
Here's Why Momentum Investors Will Love Kala Pharmaceuticals (KALA)
by Zacks Equity Research
Does Kala Pharmaceuticals (KALA) have what it takes to be a top stock pick for momentum investors? Let's find out.